JP2007507482A5 - - Google Patents

Download PDF

Info

Publication number
JP2007507482A5
JP2007507482A5 JP2006530728A JP2006530728A JP2007507482A5 JP 2007507482 A5 JP2007507482 A5 JP 2007507482A5 JP 2006530728 A JP2006530728 A JP 2006530728A JP 2006530728 A JP2006530728 A JP 2006530728A JP 2007507482 A5 JP2007507482 A5 JP 2007507482A5
Authority
JP
Japan
Prior art keywords
maleate
powder
salt
pattern including
ray diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006530728A
Other languages
English (en)
Japanese (ja)
Other versions
JP4933259B2 (ja
JP2007507482A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/003070 external-priority patent/WO2005033098A1/en
Publication of JP2007507482A publication Critical patent/JP2007507482A/ja
Publication of JP2007507482A5 publication Critical patent/JP2007507482A5/ja
Application granted granted Critical
Publication of JP4933259B2 publication Critical patent/JP4933259B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

JP2006530728A 2003-10-02 2004-09-20 ピロール置換インドリノン化合物の塩および多形 Expired - Fee Related JP4933259B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50810403P 2003-10-02 2003-10-02
US60/508,104 2003-10-02
PCT/IB2004/003070 WO2005033098A1 (en) 2003-10-02 2004-09-20 Salts and polymorphs of a pyrrole-substituted indolinone compound

Publications (3)

Publication Number Publication Date
JP2007507482A JP2007507482A (ja) 2007-03-29
JP2007507482A5 true JP2007507482A5 (cg-RX-API-DMAC7.html) 2007-11-08
JP4933259B2 JP4933259B2 (ja) 2012-05-16

Family

ID=34421700

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006530728A Expired - Fee Related JP4933259B2 (ja) 2003-10-02 2004-09-20 ピロール置換インドリノン化合物の塩および多形

Country Status (25)

Country Link
US (1) US7247627B2 (cg-RX-API-DMAC7.html)
EP (1) EP1670785B1 (cg-RX-API-DMAC7.html)
JP (1) JP4933259B2 (cg-RX-API-DMAC7.html)
KR (2) KR20060058728A (cg-RX-API-DMAC7.html)
CN (1) CN100432072C (cg-RX-API-DMAC7.html)
AR (1) AR047762A1 (cg-RX-API-DMAC7.html)
AT (1) ATE473223T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004277464B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0415022A (cg-RX-API-DMAC7.html)
CA (1) CA2540639C (cg-RX-API-DMAC7.html)
CY (1) CY1110771T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004028028D1 (cg-RX-API-DMAC7.html)
DK (1) DK1670785T3 (cg-RX-API-DMAC7.html)
ES (1) ES2348623T3 (cg-RX-API-DMAC7.html)
IL (1) IL174414A (cg-RX-API-DMAC7.html)
MX (1) MXPA06003661A (cg-RX-API-DMAC7.html)
NO (1) NO20061246L (cg-RX-API-DMAC7.html)
NZ (1) NZ546001A (cg-RX-API-DMAC7.html)
PL (1) PL1670785T3 (cg-RX-API-DMAC7.html)
PT (1) PT1670785E (cg-RX-API-DMAC7.html)
RU (1) RU2319702C2 (cg-RX-API-DMAC7.html)
SI (1) SI1670785T1 (cg-RX-API-DMAC7.html)
TW (1) TW200524921A (cg-RX-API-DMAC7.html)
WO (1) WO2005033098A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200602691B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050182122A1 (en) * 2003-11-20 2005-08-18 Bello Carlo L. Method of treating abnormal cell growth using indolinone compounds
AU2006227880A1 (en) * 2005-03-23 2006-09-28 Pfizer Products Inc. Anti-CTLA4 antibody and indolinone combination therapy for treatment of cancer
WO2007034327A1 (en) * 2005-09-20 2007-03-29 Pfizer Products Inc. Dosage forms and methods of treatment using a tyrosine kinase inhibitor
TWI384986B (zh) * 2007-01-17 2013-02-11 Lg Life Sciences Ltd 抗病毒劑之順丁烯二酸單鹽以及含有該單鹽之醫藥組成物
CN101631747B (zh) * 2007-04-04 2012-09-19 大塚化学株式会社 钛酸钾及其制造方法、以及摩擦材料和树脂组合物
JO2889B1 (en) * 2008-09-17 2015-03-15 نوفارتيس ايه جي Salts 6N - (CIS-2, 6-dimethyl morpholine-4-yl) pyridine-3-yl-methyl-4 ’- (tetrafluoromethoxy) [1,1,-2-phenyl] -3-carboxamide
RU2430361C1 (ru) * 2010-07-05 2011-09-27 Государственное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет им. В.Ф. Войно-Ясенецкого Министерства здравоохранения и социального развития Российской Федерации" Способ прогнозирования риска развития диабетической ретинопатии при сахарном диабете типа 2 у якутов
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US9851313B2 (en) * 2015-03-03 2017-12-26 Panalytical B.V. Quantitative X-ray analysis—ratio correction

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1575936A3 (ru) * 1986-04-10 1990-06-30 Е.И.Дюпон Де Немур Энд Ко.(Фирма) Способ получени 3,3-дизамещенных индолин-2-ионов или их солей
US5534522A (en) * 1995-06-07 1996-07-09 Warner-Lambert Company (R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent
DE19622489A1 (de) * 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
CA2399358C (en) * 2000-02-15 2006-03-21 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
AU2002324684B2 (en) * 2001-08-15 2006-10-05 Pharmacia And Upjohn Company Llc Crystals including a malic acid salt of N-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3H-indole-3-ylidene) methyl]-2, 4-dimethyl-1H-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
YU67702A (sh) 2001-09-28 2004-12-31 Pfizer Products Inc. Postupak za dobijanje alkansulfonil piridina
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
EP1476443A2 (en) * 2002-02-15 2004-11-17 PHARMACIA & UPJOHN COMPANY Process for preparing indolinone derivatives
HN2003000272A (es) * 2002-09-10 2008-07-29 Pharmacia Italia Spa Formulaciones que comprenden un compuesto de indolinona

Similar Documents

Publication Publication Date Title
JP2011522816A5 (cg-RX-API-DMAC7.html)
JP2009545527A5 (cg-RX-API-DMAC7.html)
JP2005518433A5 (cg-RX-API-DMAC7.html)
PL2046298T3 (pl) Farmaceutyczna postać dawkowania zawierająca farmaceutycznie dopuszczalną kompozycję solubilizującą
JP2009539994A5 (cg-RX-API-DMAC7.html)
IL181304A (en) Use of dihydroprididone for the preparation of a drug for the treatment of spinal cord dysplasia
JP2009500443A5 (cg-RX-API-DMAC7.html)
JP2008539268A5 (cg-RX-API-DMAC7.html)
JP2013509429A5 (cg-RX-API-DMAC7.html)
JP2007507482A5 (cg-RX-API-DMAC7.html)
JP2014527042A5 (cg-RX-API-DMAC7.html)
JP2013522326A5 (cg-RX-API-DMAC7.html)
JP2012505884A5 (cg-RX-API-DMAC7.html)
UA96302C2 (en) Solid dosage form comprising 2-ethoxy-1-{[2'-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]methyl}-1h-benzimidazole-7-carboxylic acid
JP2008513510A5 (cg-RX-API-DMAC7.html)
JP2008536853A5 (cg-RX-API-DMAC7.html)
JP2008516004A5 (cg-RX-API-DMAC7.html)
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
RU2015119218A (ru) Комбинация
JP2015507020A5 (cg-RX-API-DMAC7.html)
IL179777A (en) Dosage Forms Dosage Forms Dissipating Fast Dissolving Solid Form Dissolving Containing This Preparation
JP2004529117A5 (cg-RX-API-DMAC7.html)
RU2006110541A (ru) Соли и полиморфы пиррол-замещенного соединения индолинона
JP2013537901A5 (cg-RX-API-DMAC7.html)
TW200700063A (en) Oral dosage form comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione